A new study comparing the clinical effectiveness of anti–tumor necrosis factor agents and the interleukin-6 inhibitor tocilizumab (Acterma) in patients with rheumatoid arthritis found that tocilizumab outperformed anti-TNFs in terms of effectiveness and drug survival.
A new study comparing the clinical effectiveness of anti—tumor necrosis factor (TNF) agents and the interleukin-6 (IL-6) inhibitor tocilizumab (Acterma) in patients with rheumatoid arthritis (RA) found that tocilizumab outperformed anti-TNFs in terms of effectiveness and drug survival.
In the global, comparative, observational study, ACT-iON, funded by Roche and published in Arthritis Care and Research, patients with moderate to severe rheumatoid arthritis (n = 1216) who initiated biologic therapy after responding inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) were observed in routine clinical practice for 52 weeks after starting treatment with intravenous tocilizumab or an anti-TNF agent.
Data were collected between February 2012 and February 2015. The primary observation was the mean change from baseline in the Disease Activity Score 28 scale using erythrocyte sedimentation rate values (DAS28-ESR) at week 24. Secondary outcome measures included mean change from baseline in DAS28-ESR at week 52, swollen joint count (SJC), tender joint count (TJC), remission rates according to DAS28-ESR and the Clinical Disease Activity Index (CDAI), and patient-reported outcomes (PROs). Safety was assessed by monitoring adverse events (AEs), abnormalities in laboratory assessments, and vital signs.
Tocilizumab was initiated in 35% of patients (n = 423), and anti-TNF agents were initiated in 65% (n = 793).
In the anti-TNF arm, patients received the following biologics:
Patients initiating tocilizumab had a shorter mean disease duration than those initiating anti-TNF agents , as well as a slightly higher mean DAS28-ESR and SJC, and more frequent oral corticosteroid use. In the tocilizumab arm, 73.8% of patients received conventional synthetic DMARDs together with biologic therapy, as did 85.6% of patients receiving anti-TNF agents. Methotrexate was the most common concomitant DMARD.
The researchers found, with a 95% confidence interval (CI), the following:
In terms of drug survival, 14.9% of patients who initiated tocilizumab and 27.4% of those who started treatment with anti-TNF agents terminated biologic therapy
AEs and serious AEs were reported in similar proportions and rates between the 2 groups. The most common AEs were infections and infestations. Serious infections were reported in 8 (1.9%) of those receiving tocilizumab and 26 (3.3%) of those receiving anti-TNF agents. Three patients in the tocilizumab group died (2 of pneumonia, 1 of cardiac failure), and 6 patients in the anti-TNF group died (causes of death included sepsis, pneumonia, and pericardial effusion).
The researchers concluded that patients who initiated biologic treatment with tocilizumab experienced better drug survival and better clinical improvements than did those who initiated biologic treatment with anti-TNF agents.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.